NEW STUDY: Vaccine Rollout in Israel Associated with ‘Increase of Over 25%’ in ‘Emergency Cardiovascular Events Among Under-40 Population’

In a new study published in the peer-reviewed journal Scientific Reports, researchers from MIT and Ben-Gurion University report the Israeli COVID-19 “vaccine” rollout was associated with an “increase of over 25%” in “emergency cardiovascular events among [the] under-40 population.”

A new study published in the peer-reviewed journal Scientific Reports has found that “An increase of over 25%” was detected in “emergency cardiovascular events among [the] under-40 population” during January–May 2021 in Israel, compared with the years 2019–2020. The study’s authors, who performed a retrospective population-based analysis via data collected from the Israel national emergency medical services (IEMS), say “the findings raise concerns regarding vaccine-induced undetected severe cardiovascular side-effects and underscore the already established causal relationship between vaccines and myocarditis, a frequent cause of unexpected cardiac arrest in young individuals.

In the study, published April 28, 2022 and titled “Increased emergency cardiovascular events among under-40 population in Israel during vaccine rollout and third COVID-19 wave,” the authors specifically looked at the number of emergency calls into the IEMS related to cardiovascular issues—specifically calls related to acute coronary syndrome (ACS) and cardiac arrest (CA)—coupled with data on COVID-19 infection rates, as well as the respective vaccination rates over the same period of time.

The study’s time period spanned 14 months of a “normal period” before COVID-19 and vaccine rollout—from 1/1/2019 to 2/1/2020—about 10 months of a “pandemic period” with two waves of the pandemic—3/1/2022 to 12/1/2022—and about 6 months of a “pandemic and vaccination period”1/1/2022-6/1/2022—during which Israel launched its vaccination rollout in parallel to a third wave of the COVID-19 pandemic.

For their statistical analysis the authors—led by Postdoctoral Fellow with Healthcare System Engineering at Massachusetts General Hospital and with MIT’s Sloan School of Management Christopher Sun—calculated the year-to-year absolute and relative changes in emergency calls related to ACS and CA in three age groups (including 16-39, over-40, and all ages), and by gender. These changes were then calculated separately with respect to the full calendar year (2019–2020); as well as from January 1st to May 31st (2019–2021). “The January–May time period was used for comparison as it corresponds with the administration of vaccinations among the 16–39 age group in 2021.”

Sun et al. found that “Of the 30,262 cardiac arrest and 60,398 ACS calls included in the study population… 945 (3.1%) and 3945 (6.5%) calls were for patients of age 16–39, respectively, from a population of close to 3.5 million people in this age group. Of the 834,573 confirmed COVID-19 cases during the study period, 572,435 (68.6%) cases were from individuals of age 16–39. Among the 5,506,398 patients receiving their 1st vaccination dose and 5,152,417 patients receiving their 2nd vaccination dose, 2,382,864 (43.3%) and 2,176,172 (32.2%) patients were of age 16–39, respectively.

To illustrate their findings, in the graphs above are weekly counts of cardiac arrest calls (five-week centered moving-average), weekly COVID-19 cases (three-week centered moving-average), and weekly vaccination doses (three-week centered moving-average) for those between 16 and 39 during: A) January 1, 2019 through June 20, 2021 and B) October 18, 2020 through June 20, 2021 (a period encapsulating the third COVID-19 wave, as well as the vaccination distribution period).

Note how the wave of first and then second vaccine doses—the purple and blue lines respectively—are associated with a noticeable uptick in number of cardiac arrest calls. Indeed, as both 1st and 2nd vaccination dose uptake rates spike, so too do the number of calls. Similarly, as the vaccination uptake rate drops, so too do the number of calls.

In their conclusion, the authors say that:

The main finding of this study concerns… increases of over 25% in both the number of CA calls and ACS calls of people in the 16–39 age group during the COVID-19 vaccination rollout in Israel (January–May, 2021), compared with the same period of time in prior years (2019 and 2020)Moreover, there is a robust and statistically significant association between the weekly CA and ACS call counts, and the rates of 1st and 2nd vaccine doses administered to this age group. At the same time there is no observed statistically significant association between COVID-19 infection rates and the CA and ACS call counts. This result is aligned with previous findings which show increases in overall CA incidence were not always associated with higher COVID-19 infections rates at a population level as well as the stability of hospitalization rates related to myocardial infarction throughout the initial COVID-19 wave compared to pre-pandemic baselines in Israel.”

The authors also note in their conclusion that: “These results also are mirrored by a report of increased emergency department visits with cardiovascular complaints during the vaccination rollout in Germany as well as increased EMS calls for cardiac incidents in Scotland.”

Indeed, not only does this study reflect related ones from Germany and Scotland, but also a growing, robust body of evidence evincing an obvious and unequivocal link between the COVID-19 injections and myocarditis/pericarditis, as well as blood clots. As of this writing VAERS (the Vaccine Adverse Event Reporting System) contains 31,465 results for the search term “myocarditis.” For “blood clot,” there are 14,099 results.

Feature image: Science Reports / Christopher L. F. Sun, et al.

(Visited 41 times, 1 visits today)

Accessibility Toolbar